Black Diamond Therapeutics hosts webcast on updated silevertinib Phase 2 data
BDTX•Black Diamond Therapeutics will host an investor webcast on Nov. 10, 2026, at 7:30 a.m. ET, to discuss updated Phase 2 silevertinib results and FDA feedback supporting a Phase 3 path to potential accelerated approval.
1. Webcast details
Black Diamond Therapeutics will host an investor webcast Nov. 10, 2026, at 7:30 a.m. ET. The discussion will cover updated Phase 2 silevertinib results in first-line EGFR-mutated non-small cell lung cancer and FDA feedback supporting a Phase 3 path to potential accelerated approval in that patient population.
